AI assistant
USCOM LIMITED — Regulatory Filings 2022
Dec 11, 2022
65979_rns_2022-12-11_39ea4e48-80b3-46b7-963d-5f610dd5cb6a.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
ASX MEDIA RELEASE
Uscom China Recognised as Innovative Small Mediumsized Enterprise by Beijing Chaoyang DRC
SYDNEY, Australia, Monday 12[th] December 2022: Uscom Limited (ASX code: UCM) (the Company or Uscom ) today notified the market that its wholly owned subsidiary, Beijing Uscom Consulting Co., Ltd (Uscom China), was selected as one of the first Innovative Small and Medium-sized Enterprises (SMEs) by Beijing Chaoyang Development and Reform Committee (DRC). The result was formally released on the website of Chaoyang District People’s Government of Beijing Municipality on 25th November, 2022.
According to the Ministry of Industry and Information Technology of the People's Republic of China's "Interim Measures for the Gradient Cultivation and Management of High-quality SMEs", high-quality SMEs refer to the SMEs with strong innovation ability in products, technologies, management and modes, focusing on market segments with good growth. Innovative SMEs have a high level of specialization, strong innovation ability and development potential, and are the basic strength of highquality SMEs.
Uscom China is a Chinese National High-tech Enterprise and AAA credit enterprise. Its main product - USCOM 1A non-invasive hemodynamic monitor, which has been clinically verified for more than 20 years, has a high reputation in the field of hemodynamics. Global users have published over 700 papers about USCOM 1A clinical research and review, including more than 400 SCI papers. To date, 90 China funded projects have supported USCOM 1A clinical research and more than 200 Chinese papers on USCOM 1A clinical applications have been published. BP+ non-invasive central BP monitor also has more than 200 papers published worldwide, by authors from well-known universities and hospitals such as Harvard University and Cambridge University.
The selection of the first batch of innovative small and medium-sized enterprises by Beijing Chaoyang District marks another recognition of Uscom China’s innovation ability, professionalism and growth. Facing the unmet needs of non-invasive clinical diagnosis and treatment, Uscom China will increase its core technology investment, enrich its product pipeline in the cardiovascular and respiratory fields, and create more value for society.
Executive Chairman of Uscom, Professor Rob Phillips said “This is further validation of Uscom’s recognition in China as an influential innovator, and as economic activities within China begin to rebound Uscom is well positioned for growth and clinical uptake. Endorsements such as these demonstrate the regard in which Uscom, and specifically Uscom China, is held internationally and support its potential in the market.”
Uscom manufactures and markets the USCOM 1A , the Uscom BP+ , and the Uscom SpiroSonic digital ultrasonic spirometry technologies and the VENTITEST and VENTITEST-S ultrasonic ventilator calibration devices for optimising respiratory device performance.
Reference:
http://www.bjchy.gov.cn/dynamic/notice/4028805a84aa34700184ac68a21f0039.html
Uscom Limited (ABN 35 091 028 090) Suite 2, Level 8, 66 Clarence Street, Sydney, NSW, 2000, Australia T: +612 9247 4144 E: [email protected] W: www.uscom.com.au
ASX MEDIA RELEASE
==> picture [445 x 131] intentionally omitted <==
==> picture [445 x 131] intentionally omitted <==
==> picture [375 x 97] intentionally omitted <==
==> picture [375 x 97] intentionally omitted <==
Uscom Limited (ABN 35 091 028 090) Suite 2, Level 8, 66 Clarence Street, Sydney, NSW, 2000, Australia T: +612 9247 4144 E: [email protected] W: www.uscom.com.au
ASX MEDIA RELEASE
About Uscom
Uscom Limited (UCM) : An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.
The USCOM 1A : A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.
The Uscom BP+ : A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary BP+ Reporter , an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.
Uscom SpiroSonic digital multi-path ultrasonic spirometers : High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They require no calibration, are simple to disinfect, and are simple and accurate to use providing research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone apps and proprietary SpiroSonic software, SpiroReporter , with wireless interfacing to provide remote telemonitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, occupational lung disease and monitoring of pulmonary therapeutic compliance.
VENTITEST digital ultrasonic ventilator testing solution is a new system for testing ventilators. All ventilators require calibration to maintain the accuracy with which they measure the pressure, flow and volume of air they deliver. VENTITEST and VENTITEST-S, based on advanced SpiroSonic technology provides a testing solution that provides for simple and accurate testing, archiving, analysis and reporting to optimise ventilation performance.
For more information, please visit: www.uscom.com.au
Uscom Contacts Rob Phillips Brett Crowley Chairman Company Secretary [email protected]
This announcement is approved for release to the ASX by the Board of Uscom Limited.
Uscom Limited (ABN 35 091 028 090) Suite 2, Level 8, 66 Clarence Street, Sydney, NSW, 2000, Australia T: +612 9247 4144 E: [email protected] W: www.uscom.com.au